Company News

As Australia's Biggest Week in Biotech approaches, AusBiotech is celebrating four emerging companies that have joined its growing national community through AusBiotech Connect, a membership designed to support the next generation of biotechnology, medical technology and health technology innovators.

Eleven life sciences companies will spend three minutes each making their case to investors on the Gold Coast this month. They will have no slides to lean on.

Australian biotech science has never been stronger, but the conditions around it are shifting. US drug pricing, China's rise and a rethink of American research funding are changing where medicines are discovered, developed and financed.

Researchers at the Walter and Eliza Hall Institute have identified a previously overlooked type of immune cell that can recognise and kill small cell lung cancer, the deadliest form of the disease, which claims most of its patients within five years of diagnosis.

VVMF chief executive Stephen Thompson said, "We are pleased to be working with Peter Mac to evaluate the manufacturability of this AAV-based candidate and generate the process and analytical data required to inform its future development."

Biotron has announced that Glenn Gilbert, the former chief executive and managing director of Rhythm Biosciences, will join as chief executive and executive director in January 2027.

Researchers at Monash University have won more federal funding to keep studying how one of the immune system's brakes works. Their industry partner, ASX-listed Immutep, is building its drug portfolio around that same mechanism.

Tofflon Science and Technology Group will show a scale model of a modular CAR-T manufacturing facility at AusBiotech International 2026 on the Gold Coast.

The PALACROS research program was formally launched in Amsterdam this week. It brings together leading European hospitals, researchers, patient organisations, and industry partners to improve treatment for patients with locally advanced pancreatic cancer.

NeuroScientific Biopharmaceuticals has announced that US regulators have largely endorsed its plans for a Phase 2 trial of a stem cell therapy in people with Crohn's disease who have not responded to existing treatments.

Perth-based regenerative medicine company Orthocell says its nerve repair device could open a new market in prostate cancer surgery.

Argent BioPharma has recast itself as an immune science company. In an update to shareholders, it said it will now focus its resources and research on inflammatory disease after licensing CannEpil to a global partner.